Search

Filter:

Search Results

Actavis rolls out generic Lidoderm patch; Daiichi shares plunge on new FDA import restrictions;

Visterra antibody shows promise in preclinical study as universal flu vaccine. Item > NIH partners with Eli Lilly, others on rare diseases. Article > Experimental vaccine clears monkeys of HIV-like ...

Troubled Dendreon gets EC OK for Provenge; Acacia launches pivotal studies;

> Visterra antibody shows promise in preclinical study as universal flu vaccine.  Item > NIH partners with Eli Lilly, others on rare diseases.  Article > Experimental vaccine clears monkeys ...

Biotechs keep the cash pumping (for now) with more IPOs and ATMs

PhII Langer's Bind files $80M IPO as new biotech offerings go gangbusters Five Prime Therapeutics ...

Boston Scientific scores solid results for TAVR device; JenaValve nails down expanded CE mark;

promise in preclinical study as universal flu vaccine.  Item > NIH partners with Eli Lilly, others on rare diseases.  Article > Experimental vaccine clears monkeys of HIV-like virus.  More > Genia ...

Boston Scientific, OrbusNeich call cease-fire in stent fight

including the top-selling Promus Element and newly released Promus Premier. OrbusNeich first filed suit ...

UPDATED: Strides gets FDA warning for plant Mylan is buying

drug unit it is selling to Mylan ($MYL) for $1.6 billion. In a filing with the Indian stock exchange, ...

Veeva, provider of sales software to Merck, seeks up to $150M in IPO

in April that Veeva was likely to attempt an IPO this year.- here's the S-1 filing- and an article ...

Unvaccinated clusters bear brunt of bad year for measles in U.S.

the 10% of people who decline the measles vaccine are distributed. Most of the country is above the 90% immunization target, but in certain communities the vaccination rate is much lower. When a virus is introduced ...

Study links delayed vaccines to increased risk of whooping cough

prevented had they been vaccinated on time," lead study author Jason Glanz told Reuters. The link between delayed vaccinations and increased risk of disease is unsurprising, but the study delivers data ...

Visterra antibody shows promise in preclinical study as universal flu vaccine

Cambridge, MA-based Visterra has unveiled positive preclinical data showing that its lead candidate VIS410, an engineered antibody, was effective at neutralizing strains of H5N1 and H7N9 influenza in mice. The study results show potential for a universal flu vaccine that could guard against seasonal ...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »